Claims for Patent: 8,617,868

Summary for Patent: 8,617,868

Title:	Asparaginase enzyme variants and uses thereof
Abstract:	The present invention relates to newly identified asparaginase polypeptide variants of SEQ ID NO: 3 and to polynucleotide sequences that encode such novel asparaginase variants. Furthermore the invention relates to the use of these novel asparaginase variants in industrial processes.
Inventor(s):	Van Der Laan; Jan Metske (Breda, NL), Stor; Mark Cristiaan (Gouda, NL), Lange De; Ilse (Hellevoetsluis, NL), Mohrmann; Lisette (Bergschenhoek, NL)
Assignee:	DSM IP Assets B.V. (Heerlen, NL)
Application Number:	12/596,710
Patent Claims:	1. A variant of a parent polypeptide having asparaginase activity, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises substitution of an amino acid residue corresponding to any of amino acids 41, 62, 63, 76, 77, 101, 104, 106, 108, 119, 122, 123, 132, 140, 142, 143, 145, 162, 163, 169, 170, 195, 213, 217, 218, 232, 233, 234, 268, 269, 270, 272, 273, 293, 297, 298, 300, 301, 304, or 371; said positions being defined with reference to SEQ ID NO: 3, and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3. 2. A variant according to claim 1, wherein the parent polypeptide has the sequence set out in SEQ ID NO: 3. 3. A variant according to claim 1, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises substitution of an amino acid residue corresponding to any of amino acids 41, 63, 76, 77, 101, 106, 119, 122, 123, 132, 140, 145, 170, 195, 218, 232, 233, 293, 297, 300, 301, 304, or 371; said positions being defined with reference to SEQ ID NO: 3. 4. A variant according to claim 1, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises one or more of Ile at position 41, Gly or Val or Ser at position 63, Thr at position 76, Ile at position 77, Val at position 101, Pro at position 106, Asn at position 119, His at position 122, Ala at position 123, Ser at position 132, Asn at position 140, Ser at position 145, Thr at position 170, Val at position 218, Val at position 232, Val at position 233, Ser or Val at position 293, Ser at position 297, Ile at position 300, Pro at position 301, Thr at position 304, or Met at position 371; said positions being defined with reference to SEQ ID NO: 3. 5. A variant according to claim 1, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises substitution of an amino acid residue corresponding to any of amino acids 63, 76, 77, 101, 140, 170 or 293; said positions being defined with reference to SEQ ID NO: 3. 6. A variant according to claim 1, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises one or more substitution of Gly or Val at position 63, Thr at position 76, Ile at position 77, Val at position 101, Asn at position 140, Thr at position 170, Ser or Val at position 293, said positions being defined with reference to SEQ ID NO: 3. 7. A variant according to claim 1, wherein the variant comprises any one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 or SEQ ID NO: 19. 8. A variant according to claim 1 which has at least 95% homology with SEQ ID NO: 3. 9. A variant according to claim 1 which has a specific activity, which is higher than that of the parent polypeptide measured at the same pH. 10. A variant according to claim 1, wherein the variant has a pH optimum which is higher than that of the parent polypeptide. 11. A variant according to claim 1 which further comprises additional substitution of amino acid residues selected from an amino acid residue corresponding to any of amino acids 53, 64, 66, 70, 71, 73, 74, 88, 90, 91, 102, 103, 107, 109, 111, 161, 164, 168, 211, 214, 215, 216, 219, 220, 228, 235, 262, 267, 271, 295, 299, 302, 303, 310, 314, 317, 318, 319, 321, 323, 324, 325, 327, 328, 329, 330, 331, 332, 333, 334, or 335, said positions being defined with reference to SEQ ID NO: 3. 12. A variant according to claim 11 which comprises from 1 to 5 additional substitutions. 13. An isolated nucleic acid encoding the variant according to claim 1. 14. A nucleic acid construct comprising the nucleic acid sequence of claim 13 operably linked to one or more control sequences capable of directing the expression of an asparaginase in a suitable expression host. 15. A recombinant expression vector comprising the nucleic acid construct of claim 14. 16. A recombinant host cell comprising the expression vector of claim 15. 17. A method for producing an asparaginase comprising cultivating the host cell of claim 16 under conditions conducive to production of the asparaginase and recovering the asparaginase. 18. A method of producing an asparaginase polypeptide variant according to claim 1, which method comprises: a) selecting a parent asparaginase polypeptide; b) substituting at least one amino acid residue corresponding to any of 41, 62, 63, 76, 77, 101, 104, 106, 108, 119, 122, 123, 132, 140, 142, 143, 145, 162, 163, 169, 170, 195, 213, 217, 218, 232, 233, 234, 268, 269, 270, 272, 273, 293, 297, 298, 300, 301, 304, or 371; said positions being defined with reference to SEQ ID NO: 3, and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3; c) optionally substituting one or more further amino acids as defined in b); d) preparing the variant resulting from steps a)-c); e) determining the specific activity at least one pH and/or the pH optimum of the variant; and f) selecting a variant having an increased specific activity at least one pH in comparison to the parent asparaginase polypeptide and/or an increased pH optimum in comparison to the parent asparaginase polypeptide, thereby to produce an asparaginase polypeptide variant. 19. A method according to claim 18, wherein the parent asparaginase polypeptide has the sequence set out in SEQ ID NO: 3. 20. A method according to claim 18 wherein in step b) at least one amino acid residue corresponding to any of 41, 63, 76, 77, 101, 106, 119, 122, 123, 132, 140, 145, 170, 195, 218, 232, 233, 293, 297, 300, 301, 304, or 371 is substituted; said positions being defined with reference to SEQ ID NO: 3, and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3. 21. A method according to claim 20 wherein in step b) the substituted amino acid residue corresponds to one or more of Ile at position 41, Gly or Val or Ser at position 63, Thr at position 76, Ile at position 77, Val at position 101, Pro at position 106, Asn at position 119, His at position 122, Ala at position 123, Ser at position 132, Asn at position 140, Ser at position 145, Thr at position 170, Asp at position 195, Val at position 218, Val at position 232, Val at position 233, Ser or Val at position 293, Ser at position 297, Ile at position 300, Pro at position 301, Thr at position 304, or Met at position 371; said positions being defined with reference to SEQ ID NO: 3. 22. A composition comprising the variant according to claim 1. 23. Process for the production of a food product involving at least one heating step, comprising adding one or more asparaginase enzymes according to claim 1 to an intermediate form of said food product in said production process, whereby the enzyme is added prior to said heating step in an amount that is effective in reducing the level of asparaginase that is present in said intermediate form of said food product. 24. The variant of claim 1 comprising a substitution at amino acid residue 63. 25. The variant of claim 9, wherein the specific activity of the variant protein is higher than the specific activity of the parent polypeptide at least at one pH. 26. The variant of claim 25, wherein the specific activity of the variant protein is higher at a pH from 4 to 8, than the specific activity of the parent polypeptide at the same pH. 27. A variant of a parent polypeptide having asparaginase activity, wherein the variant has an amino acid sequence which, when aligned with the sequence set out in SEQ ID NO: 3, comprises one or more of: Tyr at position 53, Pro at position 64, Lys at position 73, Ala at position 74, Thr at position 76, Ile at position 77, Tyr or Pro at position 88, Val at position 90, Glu at position 91, Gly at position 111, Asp at position 195, Ser at position 211, His at position 228, Cys or His at position 262, Tyr at position 267, Ser at position 295, Ser at position 299, Ser at position 303, Val at position 310, Asp at position 314, Ile at position 317, Ala at position 319, Thr at position 321, Gly at position 324, Ser at position 330, Ala at position 332, or Glu at position 333; said positions being defined with reference to SEQ ID NO: 3, and wherein the parent polypeptide has at least 90% homology with SEQ ID NO: 3. 28. The variant of claim 27, wherein the variant has an amino acid sequence according to SEQ ID NO: 11. 29. The variant according to claim 24 which has at least 95% homology with SEQ ID NO: 3.

Details for Patent 8,617,868

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2027-04-20